An Epstein-Barr Virus-Associated Leukemic Lymphoma in a Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine for Hepatitis-Associated Aplastic Anemia
An Epstein-Barr Virus-Associated Leukemic Lymphoma in a Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine for Hepatitis-Associated Aplastic Anemia
复制标题
DOI：
10.1159/000333609
复制
发表时间：
2012-01-01
影响因子：
2.4
通讯作者：
Nakao, Shinji
中科院分区：
文献类型：
--
作者：
Ohata, Kinya;Iwaki, Noriko;Nakao, Shinji
淋巴增殖性疾病 (LPD) 通常是由 Epstein-Barr 病毒 (EBV) 在 EBV 特异性 T 细胞免疫受损的情况下诱导的不受控制的 B 细胞增殖引起，特别是当存在包括抗胸腺细胞球蛋白在内的药物免疫抑制时。我们在此介绍了一个与 LPD 相关的 EBV（EBV-LPD）的罕见病例，其中在使用兔抗胸腺细胞球蛋白治疗严重肝炎相关再生障碍性贫血 3 周后发生 LPD；患者发病5天后死于暴发性白血病淋巴瘤。我们还回顾了免疫抑制治疗后 EBV-LPD 的相关文献，并记录了 EBV 病毒载量监测的有效性以及先发制人治疗的必要性。版权所有 (C) 2011 S. Karger AG，巴塞尔
Lymphoproliferative disorders (LPDs) are generally caused by uncontrolled B-cell proliferation induced by the Epstein-Barr virus (EBV) in the setting of impaired EBV-specific T-cell immunity, particularly when there is pharmacological immunosuppression including antithymocyte globulin. We herein present an unusual case of EBV associated with LPD (EBV-LPD) in which LPD occurred 3 weeks after the use of rabbit antithymocyte globulin administered for severe hepatitis-associated aplastic anemia; the patient died of fulminant leukemic lymphoma 5 days after the onset. We also review the pertinent literature on EBV-LPD after innmunosuppressive therapy and document the efficacy of EBV viral load monitoring and the need for preemptive therapy. Copyright (C) 2011 S. Karger AG, Basel